Podcasts about diagnostic

~ Téléchargez notre guide gratuit pour réussir votre investissement locatif ! ~

Growth often begins with a simple question: What can I do better? For Courtney Shearer, the answer was tracking engagement, not just understanding. This insight led her to transform her classroom through diagnostic teaching—collecting real-time data, implementing reflection routines, and shifting ownership of learning to her students. “I wanted to know that students were being heard, being challenged, but really being seen,” she says.In this episode of Unpacking Education, fourth-grade dual language teacher and AVID Certified Educator Courtney Shearer takes us inside her journey with diagnostic teaching. Her experience provided her with the tools, collaboration, and support to reframe challenges as opportunities. From tracking hand signals and student talk time to encouraging metacognitive conversations, Courtney models what it means to reflect with purpose. Her message to fellow educators: start small, plan for joy, and celebrate both student and teacher wins along the way.Visit AVID Open Access to learn more.

Toi aussi, il t'est déjà arriver de te figer, de te sentir destabilisé·e face à certaines questions ou remarques qui t'ont remis·e en doute depuis que tu vis avec une maladie chronique ou un handicap Invisible ?

SummaryThis episode features a lively discussion on Olympic hockey, healthcare compliance, and the pitfalls of diagnostic coding. The hosts share insights on how practices often manipulate diagnoses for payment, the importance of proper documentation, and the impact of payer policies on clinical decisions.TopicsDiagnostic coding manipulationHealthcare audits and complianceImpact of payer policies on clinical decisions

Furf and Monty are back with another Pulm PEEPs Pearls episode. The topic of today’s discussion is an often discussed, but often misunderstood, test; the methacholine challenge. They’ll review when to utilize this test, how it should be performed, and the appropriate interpretation. Contributors This episode was prepared with research by Pulm PEEPs Associate Editor George Doumat. Dustin Latimer, another Pulm PEEPs Associate Editor, assisted with audio and video editing. Key Learning Points What the Test Measures Methacholine challenge is a direct bronchial provocation test of airway hyperresponsiveness (AHR), a core physiologic feature of asthma. Anyone will bronchoconstrict at high enough concentrations — the test looks for an abnormal threshold. The key endpoint is the PC20: the methacholine concentration causing a 20% fall in FEV1. Abnormal in adults: PC20 ≤ 8–16 mg/mL Test Performance Meta-analyses: pooled sensitivity ~60%, specificity ~90%. Real-world cohorts: sensitivity 55–62%, specificity 56–100% (varies by population, protocol, and threshold used). Not a standalone yes/no test — best used as part of a broader diagnostic pathway. Where It Fits in the Asthma Workup The test belongs in a stepwise approach: Step 1: Spirometry + bronchodilator response Step 2: Add FeNO and/or peak flow variability (if available) Step 3: If the picture is still unclear → methacholine challenge It is most useful for symptomatic patients with normal spirometry and no bronchodilator reversibility. Given its cost, mild risk, and discomfort, it should not be a first-line test — most asthma diagnoses do not require it. Technique and Medication Prep Technique ERS guidelines favor tidal breathing over deep inspiratory maneuvers. Deep breaths can be bronchoprotective and blunt the response, reducing sensitivity — especially in mild or well-controlled asthma. Medication Washout (to Avoid False Negatives) Medication ClassWashout PeriodShort-acting beta-agonists (SABA)≥ 6 hoursLong-acting beta-agonists (LABA)~24 hoursUltra-long-acting beta-agonists~48 hoursShort-acting anticholinergics (e.g., ipratropium)~12 hoursLong-acting muscarinic antagonists (LAMA, e.g., tiotropium)7 days Inhaled corticosteroids, leukotriene blockers, and antihistamines do not significantly affect the test acutely — continue these. Withdrawing ICS also carries its own risk for asthma patients. Practical tip: Spell out exactly what to hold and when — for both the patient and the PFT lab — at the time the test is ordered. Interpreting Results Negative Test (PC20 > 16 mg/mL) Very high negative predictive value in symptomatic adults. Makes current asthma quite unlikely (assuming proper test conduct). This is the test’s greatest strength: it is an excellent rule-out test. Positive Test (PC20 ≤ 8–16 mg/mL) More nuanced — airway hyperresponsiveness is not unique to asthma. Can be positive in: chronic cough, allergic rhinitis, COPD, and even some healthy asymptomatic individuals. A positive result raises probability but must be interpreted alongside the clinical story, variable respiratory symptoms, peak flow variability, FeNO, and ICS response. Safety and Risks Overall, the test is quite safe; significant adverse effects are rare. Temporary breathing discomfort is expected (bronchoconstriction is being induced). Severe bronchospasm is possible: A trained clinician should be available; SABA inhaler/nebulizer must be immediately on hand; a physician should be reachable in the facility. Contraindications / cautions: Avoid if FEV1 < 70% predicted or < 1–1.5 L (baseline obstruction greatly increases risk). Avoid within 3 months of an acute cardiac event (rare risk of cardiac events with unstable cardiac disease). Five Pearls — Quick Recap What it tests: Methacholine challenge is a direct test of AHR with high specificity but variable sensitivity — it belongs inside a diagnostic pathway, not as a standalone asthma test. When to use it: Most useful for symptomatic patients with normal spirometry and no bronchodilator response, after FeNO and peak flow variability have been considered. Technique and meds matter: Use tidal breathing protocol; respect washout intervals — especially the 7-day LAMA washout and 24–48 hour LABA window — to avoid false negatives. Safety: Generally safe, but can induce significant bronchoconstriction. Have a SABA available and avoid the test in patients with FEV1 < 70% predicted. Interpretation: A negative test (PC20 > 16 mg/mL) strongly argues against current asthma. A positive test raises probability but is not specific — interpret alongside the full clinical picture. References and Further Reading Coates AL, Wanger J, Cockcroft DW, Culver BH; Bronchoprovocation Testing Task Force: Kai-Håkon Carlsen; Diamant Z, Gauvreau G, Hall GL, Hallstrand TS, Horvath I, de Jongh FHC, Joos G, Kaminsky DA, Laube BL, Leuppi JD, Sterk PJ. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J. 2017 May 1;49(5):1601526. doi: 10.1183/13993003.01526-2016. PMID: 28461290. Lee, J., & Song, J. U. (2021). Diagnostic comparison of methacholine and mannitol bronchial challenge tests for identifying bronchial hyperresponsiveness in asthma: a systematic review and meta-analysis. Journal of Asthma, 58(7), 883–891. https://doi.org/10.1080/02770903.2020.1739704 Davis BE, Blais CM, Cockcroft DW. Methacholine challenge testing: comparative pharmacology. J Asthma Allergy. 2018 May 14;11:89-99. doi: 10.2147/JAA.S160607. PMID: 29785128; PMCID: PMC5957064.

In this episode of The Kula Ring, Jeff White and Carman Pirie welcome Maeve Ferguson, founder of Maeve Ferguson Consulting, to explore the power of diagnostic thought leadership. Maeve shares how sophisticated assessments go far beyond traditional quiz funnels, acting as intelligent routing engines that personalize messaging, qualify leads, and optimize sales conversations. From collapsing long B2B sales cycles to filtering out unqualified prospects, Maeve explains how diagnostics serve as both a value-delivery mechanism and a powerful data play. The conversation dives into lead classification systems, personalization at scale, and how agentic AI is transforming marketing infrastructure. For manufacturers navigating complex buying journeys, this episode reveals how diagnostic experiences can increase close rates, accelerate sales conversations, and build deeper trust with prospects.

Selon l'OMS, la schizophrénie touche environ 23 millions de personnes dans le monde. Psychose caractérisée par la perte du contact avec la réalité et par des altérations du comportement, la schizophrénie est la maladie mentale chronique la plus fréquente. Les personnes atteintes sont souvent victimes d'une forte stigmatisation qui les pousse à s'isoler. Comment déconstruire les préjugés liés à cette maladie ? Quels sont les traitements existants ?   Si les réseaux sociaux et les médias traitent de plus en plus souvent des thématiques liées à la santé mentale, les préjugés et fausses croyances associées à certaines maladies psychiatriques, comme aux personnes atteintes, sont toujours bel et bien réels. Et parmi les maladies les plus stigmatisées, on retrouve la schizophrénie. Lutter contre les idées fausses  Schizophrène : adjectif utilisé dans le vocabulaire – notamment par la classe politique – pour dévaloriser, insulter…  La schizophrénie est une atteinte encore souvent associée à des comportements agressifs, alors que si une tendance à la violence peut s'exprimer, non seulement elle n'est pas systématique, mais elle est dans la plupart des cas dirigée contre les patients eux-mêmes. Dans certains contextes culturels, la schizophrénie est également assimilée à une malédiction, à un sort potentiellement transmissible...  Autant d'idées fausses qui vont isoler, ostraciser et accentuer les souffrances des personnes concernées comme de leur entourage. Autant de préjugés qui peuvent potentiellement retarder et entraver les prises en charge. Diagnostic et prise en charge précoce  La schizophrénie est une maladie grave, qui peut se manifester par des symptômes multiples : une déconnexion du réel, des émotions inappropriées à la situation. Les personnes concernées ne sont pas forcément conscientes de leur maladie et cette psychose est susceptible d'avoir, faute de prise en charge précoce et adaptée, d'importantes conséquences sur l'organisation du quotidien, le lien avec les autres, la poursuite des activités.  Les schizophrénies, dont on peut d'ailleurs parler au pluriel, en raison de la variété des symptômes d'une personne à l'autre, vont donc nécessiter une prise en charge personnalisée, et qui va évoluer dans le temps.  Avec : Dr Méja Andrianarisoa, psychiatre en libéral sur Paris centre, au cabinet CPPND (Cabinet de Psychiatrie et Psychothérapie Notre-Dame) Dr Cheikh Mohamed Fadel Gohi, psychiatre /addictologue, directeur central au Cabinet du ministre de la Santé en Mauritanie, chargé de la coordination du Programme National de Santé Mentale et de Lutte contre les Addictions. Un reportage de Charlie Dupiot. ► En fin d'émission, nous parlerons de la baisse annoncée de la contribution française au Fonds mondial de lutte contre le sida, la tuberculose et le paludisme, la promesse de don de l'État français s'élevant à 660 millions d'euros, soit un milliard d'euros en moins que lors de la période précédente. 9 associations de lutte contre ces maladies se sont réunies pour protester contre cette baisse. Interview de Marc Dixneuf, directeur général de AIDES.  Programmation musicale :  ► Kokoroko – Da du dah  ► Fabio Brazza, Vitao – Partido alto.    À lire aussiDécouvrez les 10 finalistes du Prix Découvertes RFI 2026, et votez !

Selon l'OMS, la schizophrénie touche environ 23 millions de personnes dans le monde. Psychose caractérisée par la perte du contact avec la réalité et par des altérations du comportement, la schizophrénie est la maladie mentale chronique la plus fréquente. Les personnes atteintes sont souvent victimes d'une forte stigmatisation qui les pousse à s'isoler. Comment déconstruire les préjugés liés à cette maladie ? Quels sont les traitements existants ?   Si les réseaux sociaux et les médias traitent de plus en plus souvent des thématiques liées à la santé mentale, les préjugés et fausses croyances associées à certaines maladies psychiatriques, comme aux personnes atteintes, sont toujours bel et bien réels. Et parmi les maladies les plus stigmatisées, on retrouve la schizophrénie. Lutter contre les idées fausses  Schizophrène : adjectif utilisé dans le vocabulaire – notamment par la classe politique – pour dévaloriser, insulter…  La schizophrénie est une atteinte encore souvent associée à des comportements agressifs, alors que si une tendance à la violence peut s'exprimer, non seulement elle n'est pas systématique, mais elle est dans la plupart des cas dirigée contre les patients eux-mêmes. Dans certains contextes culturels, la schizophrénie est également assimilée à une malédiction, à un sort potentiellement transmissible...  Autant d'idées fausses qui vont isoler, ostraciser et accentuer les souffrances des personnes concernées comme de leur entourage. Autant de préjugés qui peuvent potentiellement retarder et entraver les prises en charge. Diagnostic et prise en charge précoce  La schizophrénie est une maladie grave, qui peut se manifester par des symptômes multiples : une déconnexion du réel, des émotions inappropriées à la situation. Les personnes concernées ne sont pas forcément conscientes de leur maladie et cette psychose est susceptible d'avoir, faute de prise en charge précoce et adaptée, d'importantes conséquences sur l'organisation du quotidien, le lien avec les autres, la poursuite des activités.  Les schizophrénies, dont on peut d'ailleurs parler au pluriel, en raison de la variété des symptômes d'une personne à l'autre, vont donc nécessiter une prise en charge personnalisée, et qui va évoluer dans le temps.  Avec : Dr Méja Andrianarisoa, psychiatre en libéral sur Paris centre, au cabinet CPPND (Cabinet de Psychiatrie et Psychothérapie Notre-Dame) Dr Cheikh Mohamed Fadel Gohi, psychiatre /addictologue, directeur central au Cabinet du ministre de la Santé en Mauritanie, chargé de la coordination du Programme National de Santé Mentale et de Lutte contre les Addictions. Un reportage de Charlie Dupiot. ► En fin d'émission, nous parlerons de la baisse annoncée de la contribution française au Fonds mondial de lutte contre le sida, la tuberculose et le paludisme, la promesse de don de l'État français s'élevant à 660 millions d'euros, soit un milliard d'euros en moins que lors de la période précédente. 9 associations de lutte contre ces maladies se sont réunies pour protester contre cette baisse. Interview de Marc Dixneuf, directeur général de AIDES.  Programmation musicale :  ► Kokoroko – Da du dah  ► Fabio Brazza, Vitao – Partido alto.    À lire aussiDécouvrez les 10 finalistes du Prix Découvertes RFI 2026, et votez !

Despite major advances in our understanding of the biology of mental health disorders,  there's no blood test or brain scan that will confirm if you have depression, anxiety, PTSD, or any other psychiatric illness.  And yet, the American Psychiatric Association recently announced that it will be including biomarkers for mental conditions in the next edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM), which guides diagnosis and treatment of mental illness. So how close are we to pinpointing the biological markers of mental illness, and what does that mean for diagnosis? It's complicated.  Host Flora Lichtman untangles some of this science with psychiatry researcher John Krystal. Guest: Dr. John Krystal is a professor of psychiatry, neuroscience, and psychology at the Yale School of Medicine. Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

In this solo episode, Brad shares a few recent herd-health case studies from his dairy, highlighting the value of diagnostics and transparency.He walks through two calf losses—one at 60 days old and another at 9 months. Both animals had been treated for common issues but continued to decline. Necropsies revealed severe heart abnormalities in each case (thin, underdeveloped ventricles), pointing toward possible genetic or nutritional causes. The takeaway: without a necropsy, these would have remained unexplained losses.Brad also discusses a recent abortion in a dry cow. Diagnostic testing ruled out BVD and IBR and identified Citrobacter sp., an environmental organism found in manure, soil, and bedding that can contribute to abortions. He suspects environmental exposure in wintered dry cows may have played a role.Overall, the episode emphasizes investigating unexpected losses, using lab diagnostics, and learning from on-farm challenges as spring calving approaches.Questions, comments, scathing rebuttals? -> themoosroom@umn.edu or call 612-624-3610 and leave us a message!Linkedin -> The Moos RoomTwitter -> @UMNmoosroom and @UMNFarmSafetyFacebook -> @UMNDairyYouTube -> UMN Beef and Dairy and UMN Farm Safety and HealthInstagram -> @UMNWCROCDairyExtension WebsiteAgriAmerica Podcast Directory 

In Week 8 of our Follow Me series with Pastor Dave Mudd we dive deep into the "Up" rhythm of Jesus' life, exploring how true transformation begins with our private intimacy with the Father. Are you living to please God, or are you caught in the trap of people-pleasing and performance? Pastor Dave challenges us to move away from duty and guilt, discovering a life of delight through daily devotion. Learn how a heart aligned with God's will creates a "kingdom impact" that is courageous, consistent, and contagious. Watch to discover how spending time with God is the key to living the gospel in every area of your life.Key Takeaways:- Relationship Over Religion: Discover why obedience should flow from affection and delight rather than obligation, guilt, or fear.- The Power of Private Devotion: Understand why you cannot live to please God publicly if you do not meet with Him privately.- Overcoming People-Pleasing: Learn to identify and lay down the "silent rival" of seeking human approval so you can be a true servant of Christ.- Kingdom Impact: See how a life aligned with the Father naturally produces peace, courage, and spiritual authority that others can sense.- The Diagnostic of Devotion: Use a simple daily question—"What would please the Father today?"—to shift your reference point from horizontal to vertical.

In this episode of Podcast360, Norman Weinberg, MD, a retired primary care internist with over 40 years of experience, discusses the intricacies of managing physician behavior and diagnostic errors.

Le repos n'est pas une récompense, c'est un outil stratégique.Le 15 février 2026, mon corps a tiré la sonnette d'alarme pour la deuxième fois. Diagnostic : péricardite aiguë. Forcé à l'immobilité totale, j'ai dû confronter ce vide que nous fuyons tous en tant qu'entrepreneurs.Dans cet épisode, je te partage pourquoi la culture du "hustle" permanent est un mirage qui détruit ta clarté et ta performance. J'ai découvert que c'est précisément dans l'absence d'action que naissent les meilleures idées et les décisions stratégiques les plus puissantes.0:00 – Le choc : Deuxième péricardite en 5 ans. Marco revient sur l'événement qui l'a forcé à s'arrêter brutalement et le timing ironique avec ses 7 ans de sobriété.1:25 – La culture de l'occupation vs La performance réelle. Pourquoi nous glorifions le surmenage alors que les athlètes de haut niveau savent que la récupération fait partie de l'entraînement.2:10 – Les 3 leçons du repos forcé. Découverte du repos physique profond, de la clarté d'esprit organique et du recul stratégique sur son entreprise.5:28 – Ma nouvelle stratégie : La semaine de "Vide Intentionnel". Marco explique son plan de prendre une semaine de recul toutes les 8 semaines, sans mandats clients ni création de contenu.7:14 – Vaincre la peur de s'arrêter. Comment affronter les "Bitch Voices" qui nous disent qu'on va perdre notre momentum ou nos revenus.9:04 – Bâtir des systèmes pour être libre. L'importance de l'automatisation et de l'IA pour que le business tourne sans notre présence constante.

 In this episode, Neil Roy, MD, MBA, FACEP, CPE, Vice President of Diagnostic and Operative Services and Chief Medical Officer at Adventist HealthCare, shares how marketplace rounds, high risk discharge clinics, and remote monitoring cut length of stay by up to 15 percent and lowered readmissions below 10 percent, while strengthening physician engagement and preparing for AI driven patient flow innovation under Maryland's global budget model.

Fertility care is undergoing a significant shift as new diagnostic technologies offer deeper insight into reproductive health. OTO Fertility focuses on predicting the likelihood of IVF success before treatment begins, giving couples clarity at a stage where uncertainty has traditionally dominated the process. The system uses a wearable device that captures physiological signals and converts them into predictive metrics, offering a noninvasive method for understanding fertility readiness.The challenge addressed by this technology is substantial. IVF remains expensive, time‑consuming, and emotionally demanding, yet the success rate for a single transfer remains low. Many couples undergo multiple cycles without clear guidance on their likelihood of success. By providing predictive insight before treatment, the system aims to reduce unnecessary cycles, lower financial burden, and support more informed decision‑making.Physiological Monitoring and Predictive ModelingThe OTO Fertility device performs medical‑grade ECG and EEG measurements, capturing data from multiple physiological systems. These include cardiac activity, central and autonomic nervous system responses, hormonal regulation patterns, and energy supply indicators. Dozens of body signals are synthesized into a set of metrics that correlate with fertility outcomes. These metrics are then combined into a single index that reflects the couple's overall fertility readiness.Both partners participate in the process, allowing the system to evaluate male and female factors independently and together. This dual‑side approach supports a more complete understanding of fertility challenges, including those that may not be detected through traditional testing. The system also supports natural conception by identifying physiological patterns that can be optimized without clinical intervention.Personalized Guidance Through AIOnce the fertility index is generated, the system provides personalized recommendations designed to improve physiological readiness. These recommendations are based on lifestyle factors that influence fertility, including activity levels, rest, recovery, nutrition, sleep, and stress management. The guidance is tailored to each individual and delivered through the accompanying application, creating a structured pathway for improvement.The use of AI allows the system to adapt recommendations as new data is collected. Daily measurements support continuous monitoring, enabling couples to track progress and understand how their bodies respond to changes. This dynamic approach contrasts with traditional fertility diagnostics, which often rely on static snapshots taken at a single point in time.Broader Fertility Insights and Lifecycle SupportThe technology also provides insight into previously unexplained fertility challenges. A significant portion of infertility cases fall into the unexplained category, where standard tests show no clear cause. By analyzing physiological patterns across multiple systems, the device offers a new layer of understanding that can help clarify these cases.The system extends beyond conception, offering support during pregnancy and postpartum. This continuity allows couples to remain engaged with their physiological health throughout the entire fertility journey. The solution is delivered in partnership with treating physicians and virtual clinics, integrating seamlessly into existing care pathways.ConclusionOTO Fertility introduces a predictive diagnostic system designed to improve IVF outcomes and support natural conception through physiological monitoring and AI‑driven guidance. By providing insight into fertility readiness, offering personalized recommendations, and addressing both partners' health, the system creates a more informed and supportive pathway for couples seeking to build their families. As fertility challenges continue to rise globally, technologies that deliver clarity, personalization, and noninvasive insight are becoming essential components of modern reproductive care.Interview by Don Baine, The Gadget Professor.Sponsored by: Get $5 to protect your credit card information online with Privacy. Amazon Prime gives you more than just free shipping. Get free music, TV shows, movies, videogames and more. Secure your connection and unlock a faster, safer internet by signing up for PureVPN today.

Fertility care is undergoing a significant shift as new diagnostic technologies offer deeper insight into reproductive health. OTO Fertility focuses on predicting the likelihood of IVF success before treatment begins, giving couples clarity at a stage where uncertainty has traditionally dominated the process. The system uses a wearable device that captures physiological signals and converts them into predictive metrics, offering a noninvasive method for understanding fertility readiness.The challenge addressed by this technology is substantial. IVF remains expensive, time‑consuming, and emotionally demanding, yet the success rate for a single transfer remains low. Many couples undergo multiple cycles without clear guidance on their likelihood of success. By providing predictive insight before treatment, the system aims to reduce unnecessary cycles, lower financial burden, and support more informed decision‑making.Physiological Monitoring and Predictive ModelingThe OTO Fertility device performs medical‑grade ECG and EEG measurements, capturing data from multiple physiological systems. These include cardiac activity, central and autonomic nervous system responses, hormonal regulation patterns, and energy supply indicators. Dozens of body signals are synthesized into a set of metrics that correlate with fertility outcomes. These metrics are then combined into a single index that reflects the couple's overall fertility readiness.Both partners participate in the process, allowing the system to evaluate male and female factors independently and together. This dual‑side approach supports a more complete understanding of fertility challenges, including those that may not be detected through traditional testing. The system also supports natural conception by identifying physiological patterns that can be optimized without clinical intervention.Personalized Guidance Through AIOnce the fertility index is generated, the system provides personalized recommendations designed to improve physiological readiness. These recommendations are based on lifestyle factors that influence fertility, including activity levels, rest, recovery, nutrition, sleep, and stress management. The guidance is tailored to each individual and delivered through the accompanying application, creating a structured pathway for improvement.The use of AI allows the system to adapt recommendations as new data is collected. Daily measurements support continuous monitoring, enabling couples to track progress and understand how their bodies respond to changes. This dynamic approach contrasts with traditional fertility diagnostics, which often rely on static snapshots taken at a single point in time.Broader Fertility Insights and Lifecycle SupportThe technology also provides insight into previously unexplained fertility challenges. A significant portion of infertility cases fall into the unexplained category, where standard tests show no clear cause. By analyzing physiological patterns across multiple systems, the device offers a new layer of understanding that can help clarify these cases.The system extends beyond conception, offering support during pregnancy and postpartum. This continuity allows couples to remain engaged with their physiological health throughout the entire fertility journey. The solution is delivered in partnership with treating physicians and virtual clinics, integrating seamlessly into existing care pathways.ConclusionOTO Fertility introduces a predictive diagnostic system designed to improve IVF outcomes and support natural conception through physiological monitoring and AI‑driven guidance. By providing insight into fertility readiness, offering personalized recommendations, and addressing both partners' health, the system creates a more informed and supportive pathway for couples seeking to build their families. As fertility challenges continue to rise globally, technologies that deliver clarity, personalization, and noninvasive insight are becoming essential components of modern reproductive care.Interview by Don Baine, The Gadget Professor.Sponsored by: Get $5 to protect your credit card information online with Privacy. Amazon Prime gives you more than just free shipping. Get free music, TV shows, movies, videogames and more. Secure your connection and unlock a faster, safer internet by signing up for PureVPN today.

Thanks to our Partners, NAPA TRACS, Today's Class, KUKUI, and Pit Crew Loyalty Watch Full Video Episode Host Carm Capriotto dives into the untapped power of Shop Management Systems (SMS) with business coach Dave Schedin and Ben Dexter, National Training Manager at NAPA TRACS. Together, they reveal how two often-overlooked tools, categories and canned jobs, can dramatically improve shop efficiency, consistency, and profitability. The conversation highlights how a smarter system setup leads to faster workflows, clearer data, and stronger decision-making. Key Topics Discussed Unlocking the Power of Categories: Dave Schedin explains the importance of tracking three core labor types: Diagnostic, Preventative Maintenance, and Repair. When categorized correctly, shop owners can pinpoint exactly where time and money are gained—or lost. Building the “Superhighway” to Faster Estimates: Schedin compares developing Canned Jobs to constructing a freeway: it takes an upfront investment of time, but once built, it enables rapid, efficient estimating. Professional Communication: Canned jobs help replace vague descriptions with clear, value-focused explanations. This allows newer advisors to communicate like seasoned professionals while ensuring consistent pricing, messaging, and storytelling across the shop. Turning Data into Profit: Ben Dexter reinforces the principle of “garbage in, garbage out”: without clean, organized data, shop owners are simply guessing. By mastering categories and canned jobs, shop owners can turn their management system into a powerful engine for clarity, consistency, and long-term profitability. Timestamps 00:00:00 – Introduction 00:03:15 – The Three Labor Categories (Diagnostic, PM, Repair) 00:05:45 – Creating Smart Warranty Categories 00:08:20 – Data Integrity: “Garbage In, Garbage Out” 00:14:15 – Canned Jobs & Professional Storytelling 00:16:30 – “Level 10” Jobs & Built-In Parts Triggers 00:18:00 – Reducing Advisor Cognitive Load 00:19:45 – Generic Jobs vs. Vehicle-Specific “Pro Jobs” 00:22:30 – Helping New Advisors Sound Like Pros 00:25:00 – Writing Complex Estimates in 2–3 Minutes 00:29:15 – The ROI: 15–20% Sales Growth Potential 00:31:00 – Building the Estimating “Superhighway” Dave Schedin, CompuTrek Automotive Management Systems. Dave's previous episodes HERE Ben Dexter, National Training Manager, NAPA TRACS. Find Ben's other episodes HERE Thanks to our Partner, NAPA TRACS NAPA TRACS will move your shop into the SMS fast lane with onsite training and six days a week of support and local representation. Find NAPA TRACS on the...

Pour l'épisode #334 je recevais Alexis Ducarouge. On en débrief avec Jean-Christophe.🎙️ Soutenez le podcast If This Then Dev ! 🎙️ Chaque contribution aide à maintenir et améliorer nos épisodes. Cliquez ici pour nous soutenir sur Tipeee 🙏Archives | Site | Boutique | TikTok | Discord | Twitter | LinkedIn | Instagram | Youtube | Twitch | Job Board |Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In this episode of I Thought You'd Like to Know, Marcus Peter of Ave Maria Radio Interviews Stephen Rouhana on his book The King and Queen are Naked: Establishment Failures based on Scientific, Medical, and Psychiatric Research on “Gender Dysphoria” (February 9, 2026)This book is the result of analysis of the literature on Gender Dysphoria published in journals of psychology, psychiatry, and medicine, and in other relevant publications.In part one, Dr. Rouhana starts from basic definitions and leads the reader through the maze of articles and opinions on the subject to the unavoidable conclusion that the gender identity issues underlying Gender Dysphoria do constitute a mental disorder. He examines how the current recommendations in the Diagnostic and Statistics Manual of Mental Disorders (DSM) published by the American Psychiatric Association have been intentionally written to mislead the general public and medical insurance companies.In part two, Dr. Rouhana explores what ethical treatments are, and are not, for Gender Dysphoria given the conclusions from part one.In part three, he explores what the Catholic Church has taught on this topic, from the perspective of faith and philosophy. Each part ends with proposed actions to truly help those suffering with this issue.The King and Queen are Naked: Establishment Failures based on Scientific, Medical, and Psychiatric Research on “Gender Dysphoria” by Stephen W. Rouhana, Ph.D. | En Route Books and Media

Au moment où le ministre de la Ville et du Logement, Vincent Jeanbrun vient de défendre au Sénat la proposition de loi (PPL) portée sénatrice centriste du Pas-de-Calais Amel Gacquerre visant à clarifier les obligations de rénovation énergétique des logements et à sécuriser leur application en copropriété, les réactions des parlementaires experts sur le sujet commencent à réagir. Car le risque selon Vincent Jeanbrun, interrogé sur Public Sénat le mardi 17 février 2026 , « c'est que 700 000 logements sortent du parc locatif à cause d'un Diagnostic de performance énergétique (DPE) pas assez bon. » L'idée du ministre ? « C'est de continuer à louer avec l'engagement de rénover le bien en trois en ou cinq ans », explique-t-il sur la chaîne parlementaire. De son côté, le groupe politique Rassemblement National discret jusqu'à l'an dernier sur la rénovation énergétique monte au créneau par la voix de Frédéric Falcon, député de l'Aude (circonscription de Narbonne) et ancien professionnel du secteur vient justement de rencontrer justement le ministre du Logement pour aborder avec lui les problématiques autour du DPE et lui faire de ses inquiétudes sur cette proposition de loi Gacquerre. « De base au RN qui a déjà proposé de supprimer MaPrimeRénov' et de la remplacer par des prêts aux ménages à taux zéro, nous sommes opposés aux contraintes du DPE pour la location des logements, affirme le monsieur Logement du parti de Marine Le Pen. Instaurer un calendrier depuis le 1er janvier 2025 a toujours été inconcevable et cela créé 75 % d'annonces en moins de trois ans… » Frédéric Falcon s'interroge : « Cette PPL fait appel à un juge le temps des travaux et qu'est-ce qui se passe après s'il y a une intervention du juge qui a baissé le loyer et malgré les travaux ? Le propriétaire-bailleur alors sera condamné à avoir un loyer minoré et cette situation ouvre à plein de contentieux. » Autre risque selon lui : « Cela va tétaniser les propriétaires qui ont souvent un à deux logements. On lance les warning ! »

Au moment où le ministre de la Ville et du Logement, Vincent Jeanbrun vient de défendre au Sénat la proposition de loi (PPL) portée sénatrice centriste du Pas-de-Calais Amel Gacquerre visant à clarifier les obligations de rénovation énergétique des logements et à sécuriser leur application en copropriété, les réactions des parlementaires experts sur le sujet commencent à réagir. Car le risque selon Vincent Jeanbrun, interrogé sur Public Sénat le mardi 17 février 2026 , « c'est que 700 000 logements sortent du parc locatif à cause d'un Diagnostic de performance énergétique (DPE) pas assez bon. » L'idée du ministre ? « C'est de continuer à louer avec l'engagement de rénover le bien en trois en ou cinq ans », explique-t-il sur la chaîne parlementaire. De son côté, le groupe politique Rassemblement National discret jusqu'à l'an dernier sur la rénovation énergétique monte au créneau par la voix de Frédéric Falcon, député de l'Aude (circonscription de Narbonne) et ancien professionnel du secteur vient justement de rencontrer justement le ministre du Logement pour aborder avec lui les problématiques autour du DPE et lui faire de ses inquiétudes sur cette proposition de loi Gacquerre. « De base au RN qui a déjà proposé de supprimer MaPrimeRénov' et de la remplacer par des prêts aux ménages à taux zéro, nous sommes opposés aux contraintes du DPE pour la location des logements, affirme le monsieur Logement du parti de Marine Le Pen. Instaurer un calendrier depuis le 1er janvier 2025 a toujours été inconcevable et cela créé 75 % d'annonces en moins de trois ans… » Frédéric Falcon s'interroge : « Cette PPL fait appel à un juge le temps des travaux et qu'est-ce qui se passe après s'il y a une intervention du juge qui a baissé le loyer et malgré les travaux ? Le propriétaire-bailleur alors sera condamné à avoir un loyer minoré et cette situation ouvre à plein de contentieux. » Autre risque selon lui : « Cela va tétaniser les propriétaires qui ont souvent un à deux logements. On lance les warning ! »

Dr. Halley Alexander and Dr. Alissa M. D'Gama discuss genetic testing for infantile epilepsies.  Show citation:  Nguyen JNH, Lachgar-Ruiz M, Higginbotham EJ, et al. Diagnostic Yield of Comprehensive Reanalysis After Nondiagnostic Short-Read Genome Sequencing in Infants With Unexplained Epilepsy. Neurology. 2026;106(6):e214645. doi:10.1212/WNL.0000000000214645  Show transcript:  Dr. Halley Alexander:  Hi, this is Halley Alexander with today's Neurology Minute, and I'm here with Dr. Alissa D'Gama from Boston Children's Hospital and Harvard Medical School, and we just finished recording a full-length podcast about some exciting new work in genetic testing for infantile onset epilepsies. Alissa, can you tell us what you found briefly and why it's important for neurology care? Dr. Alissa D'Gama:  Infantile epilepsies are relatively common, and they're associated with substantial burden of disease, and we know that identifying underlying genetic causes can impact clinical care. It's important for emerging precision therapies. But even after genome sequencing, which is the most comprehensive clinical genetic testing currently available, most infants remain genetically unsolved. And so what we did was take that genome sequencing data and reanalyze it for a cohort of infants who had unexplained non-acquired epilepsy and non-diagnostic genome sequencing, and in about 5% of cases, our reanalysis was able to identify a genetic diagnosis, and all of these diagnoses had impact on clinical care for their infants and their families. In some cases, we could incorporate new information, either new clinical information about the patient or new scientific methods or information about disease associations, and in other cases, we were able to incorporate new analysis methods to identify variants. And so our findings suggest that implementing reanalysis for infants or any individual with epilepsy within a year or two of non-diagnostic testing may be useful. Dr. Halley Alexander:  Thank you so much, and you can find a lot more details by listening to the full-length podcast, which is available now on the Neurology podcast, and you can find the full article in the March 10th issue of Neurology or online at neurology.org. As always, thanks for tuning in for today's Neurology Minute. 

In this episode of the Health Coach Academy Podcast, we sit down with Maeve Ferguson, former Big Four consultant turned online business strategist, to unpack one of the most underrated but powerful marketing tools in the coaching industry: diagnostic quizzes and score-based assessments. Maeve shares how health coaches, consultants, and experts can transform their intellectual property into scalable lead-qualification systems that attract high-quality, high-ticket clients — without wasting hours on unqualified discovery calls. If you've ever wondered how quizzes actually work behind the scenes — or why some coaches quietly scale to multi-six-figure and seven-figure businesses — this episode pulls back the curtain.

În Episodul 167 din Thinking Made Visible am stat de vorbă cu Adriana Mocan despre identitate, disciplină și ce se întâmplă atunci când viața îți schimbă complet ritmul.Antreprenor, mamă, mereu în mișcare, genul de om care funcționează pe structură, plan și soluții. O minte pragmatică, orientată spre construcție.În 2019, într-o dimineață la ora 5, corpul ei nu a mai răspuns - diagnosticul a fost scleroză multiplă, formă rară și agresivă. Au urmat luni de investigații, căutări, întrebări, second opinions, studii citite și un plan construit pas cu pas. Adriana a ales să facă autotransplant de celule stem, într-un context dificil, iar recuperarea a însemnat ani de muncă susținută, disciplină și reconstrucție zilnică.Ne-am dorit ca această conversaţie să fie despre responsabilitate, cum transformi frica în structură și despre cum identitatea ta se reconfigurează atunci când standardele rămân aceleași, iar corpul are alt ritm.Intro (00:00)Cine era Adriana, în 2019? (04:10)Care a fost momentul din 2019 care i-a schimbat viața (04:58)Diagnostic scleroză multiplă (09:32)A plecat singură în Rusia pentru transplant (12:57)Primul an după transplant (27:51)„Cine sunt eu acum?” (33:22)Adriana care mută munții și Willness (36:43)Mesaj pentru persoanele cu acest diagnostic (41:40)Mesaj pentru persoanele din familia celui diagnosticat cu scleroză multiplă (47:20)Conferință în SUA - invitată ca speaker (53:19)Pacienții din România (55:49)Viziunea ei pentru Willness (57:18)Outro (1:09:13)

Are you up to date on HER2 testing best practices? Join our expert panel and discover the critical updates that guide treatment selection. Credit available for this activity expires: 2/17/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/navigating-her2-spectrum-breast-cancer-evolving-diagnostic-2026a10004ea?ecd=bdc_podcast_libsyn_mscpedu

Episode 5: The Polymathic Crime/Murder Board | A Diagnostic for an Age Addicted to Verdicts . What if our biggest threat to justice isn't corruption or ignorance, but our addiction to certainty? . In an age of instant outrage, viral accusations, and premature conclusions, we confuse speed with truth and emotional relief with accountability. Verdicts arrive long before understanding does, and they feel righteous, even when they're wrong. . In this episode of The Polymathic Perspective, we step into a radically different posture. Not a verdict. A diagnostic. . Using the logic of an FBI murder board, this episode examines why the human nervous system rushes to conclusions, how identity hijacks inquiry, and why simplifying harm into heroes and villains so often protects the systems that produce it. . You'll explore: Why certainty is neurologically soothing, and epistemically dangerous How the Central Park Five exposed what happens when narrative speed outruns investigative discipline Why harm often looks like alignment, not deviation How proxy wars reveal invisible beneficiaries and misplaced accountability Why real change always carries cost, and why cost is the only reliable evidence How the Epstein files function as an epistemic stress test, not a list of verdicts . This episode will frustrate anyone looking for outrage, moral shortcuts, or clean villains. It's designed for listeners willing to sit with uncertainty long enough for truth to survive pressure. Because justice that can't withstand scrutiny isn't justice at all... It's theater. . If you're ready to trade certainty for coherence, and outrage for accuracy, this episode will change how you listen to everything that comes next. About The Polymathic Perspective Podcast . The Polymathic Perspective is a weekly practice for integrative thinkers, leaders, and curious minds who refuse to collapse complexity into comforting lies. Each episode examines how meaning, identity, incentives, and systems interact beneath the stories we're told. This is not a podcast for conclusions. It's a podcast for diagnostic clarity.

By David Stephen who looks at biomarkers in this article. Will there ever be a biological test for human intelligence, to explore how to improve it in the age of AI? Like, would it ever be possible to test a human being for intelligence by some biological factor, and how to make it competitive against AI? The same question applies to mental disorders. Would there ever be biological tests, to know what therapies would work? These, at least for mental disorders, is what the American Psychiatric Association is seeking. Biomarkers for Psychiatry, Human Intelligence There is a recent [January 28, 2026] press release, APA Releases Roadmap for the Future of the DSM, stating that, "The American Psychiatric Association (APA) has released a series of papers offering a proposed roadmap for the future of the Diagnostic and Statistical Manual of Mental Disorders (DSM). The five papers, including the Initial Strategy for the Future of the DSM and four accompanying commentaries, are the result of the committee's year of structured debate and consideration of long-standing critiques and rapid scientific advances. They propose a forward-looking model for the evolution of the DSM. They also suggest changing the name from Diagnostic and Statistical Manual to Diagnostic and Scientific Manual to better reflect its scientific and global scope. The four accompanying papers address structure and dimensions of the DSM; the role of biomarkers and biological factors in diagnosis; vision for incorporating socioeconomic, cultural and environmental determinants of health and intersectionality; and the role of functioning and quality of life in psychiatric diagnosis." Conceptual Biomarkers and Theoretical Biological Factors for Psychiatric and Intelligence Nosology What are the options for biomarkers in the brain for mental disorders? Would they be different or similar to those for human intelligence? What are the universal components in the brain, for functions of human life and experiences? Can a model be developed on these components and their mechanisms, first to explain labels and next to scope out biomarkers? The problem before psychiatry is not just the distance to developing tests but to even describe what is happening in the brain for the labels of conditions. Mood disorders have several descriptions. But what are their components in the brain and the course of their actions. Answering these questions can put conditions in perspective as parallels are sought, before adventuring into biomarkers development. The same applies to human intelligence. Now, artificial intelligence is in an intense acceleration. There are valuable labor tasks that will be lost due to AI. And, because intelligence is the last frontier of superiority for humanity among organisms, it will be important to seek to map it, and explore it for problem-solving. This is the postulation in Conceptual Biomarkers and Theoretical Biological Factors for Psychiatric and Intelligence Nosology. The options are electrical and chemical signals as the components of functions in the brain. It states that neurons are conduits or bridges that signals use to carry out functions. It also states that signals are in sets in cluster of neurons. It is possible to use signals, conceptually, to explain and display all disorders in the DSM. It is also possible to use them to develop, explain, and display the two main types of human intelligence [improvement and operational], to ensure that options are broadened towards survival in the age of AI. This seminal work on conceptual brain science could be completed by August, 2026, moving psychiatry and intelligence forward, as well as neurology. David Stephen currently does research in conceptual brain science with focus on the electrical and chemical configurators for how they mechanize the human mind with implications for mental health, disorders, neurotechnology, consciousness, learning, artificial intelligence and nurture. He was a visiting scholar in m...

Boala e efortul funcțiilor vitale de a elibera organismul din starea provocată de încălcarea legilor sănătății. Chiar în fața cancerului, există perspectivă spirituală. Dumnezeu ne cheamă să privim cauza, nu doar efectele. Suferința separă zgura de aurul caracterului creștin, curățind metalul prețios. Citește acest devoțional și multe alte meditații biblice pehttps://devotionale.ro#devotionale #devotionaleaudio

Summary In this episode of the Future of Dermatology podcast, Dr. Faranak Kamangar and Dr. Peter Lio discuss significant advancements in dermatology, including the recent approval of an ICD 10 code for topical steroid withdrawal, the exploration of botanicals in skin treatment, and the emerging understanding of the gut-skin connection. They also delve into the role of GLP medications in managing skin conditions and the exciting future developments in dermatology, particularly in the treatment of atopic dermatitis. Read the referenced documents at the following sites: - Ancient botanicals and the skin: Defining dermatologic ethnophytoconvergence as a translational framework for pharmacognosy: https://doi.org/10.1016/j.jdrv.2025.12.008 - The Gut-Skin Axis: Exploring the Role of SCFAs, Obesity, and GLP-1 Receptor Agonists in Atopic Dermatitis: https://jintegrativederm.org/article/view/109 - Topical Steroid Withdrawal is a Targetable Excess of Mitochondrial NAD+: https://www.medrxiv.org/content/10.1101/2024.04.17.24305846v1.full-text - Jennifer Fugo information: https://www.skinterrupt.com/book-a-session/ Takeaways - The CDC has approved an ICD 10 code for topical steroid withdrawal. - This approval allows for better study and understanding of TSW. - Diagnostic criteria for TSW are still being developed. - Topical steroid withdrawal may overlap with severe atopic dermatitis. - Non-steroidal treatments are becoming more prominent in dermatology. - Botanicals have been used across cultures for skin treatment. - The gut-skin connection is gaining attention in dermatology. - GLP medications may play a significant role in dermatological treatments. - The future of dermatology is promising with new treatments on the horizon. - A holistic approach to skin health is essential for effective treatment. Chapters 00:00 - Introduction to Dermatology Innovations 01:43 - Topical Steroid Withdrawal Breakthroughs 06:53 - Exploring Botanicals in Dermatology 09:15 - Gut-Skin Connection and Metabolic Health 13:42 - The Role of GLPs in Dermatology 19:42 - Future of Dermatology: Exciting Developments

Dr. Halley Alexadner talks with Dr. Alissa M. D'Gama about genetic testing for infantile epilepsies.  Read the related article in Neurology®.  Disclosures can be found at Neurology.org. 

Pastors don't start cynical or burned out. But somewhere along the way, the wine runs out and we keep preaching, leading, and carrying burdens we were never meant to carry.In a Practically Pastoring Conference session, Tim Wildsmith walks through John 2:1–11 and connects it with Matthew 11:28–30, offering a simple but piercing invitation: name the need, surrender the burden, and pursue soul rest in Jesus before ministry emptiness turns into something worse.Follow Tim Wildsmith:Website: https://timwildsmith.comYouTube: https://www.youtube.com/@timwildsmithInstagram: https://www.instagram.com/timwildsmithX: https://x.com/timwildsmithFacebook: https://www.facebook.com/TimWildsmith/Timestamps:00:00 – Tim's story (Belmont, YouTube, Bible nerd life)03:44 – Why this talk (ministry grind, running on empty)05:42 – Reading: John 2:1–11 (Wedding at Cana)08:02 – When the wine runs out (ministry parallels)10:29 – Mary's model: “They have no more wine” (name the need)12:57 – Burnout realities + overwhelming expectations15:28 – Matthew 11:28–30: where do you go for rest?19:23 – The “rock” exercise: why we don't want to set burdens down22:12 – What is the soul? (Dallas Willard) + “rest for your souls”25:12 – Take His yoke: you can't wear both yokes27:23 – Back to John 2: obedience makes space for Jesus to work29:10 – Production vs. obedience (faithfulness, not self-sufficiency)30:04 – Diagnostic questions: where has the wine run out?32:07 – Practical step: name the need (even hard conversations)36:24 – Prayer for peace, surrender, and courageLinks:

Dr. Nyree Whitley, Chief Clinical Officer at mydentist & Dr. Gordon Barfield, Senior Clinical Manager at Overjet discuss: What a clinician-first diagnostic strategy looks like The dental regulatory & clinical environment in the UK Advice for clinical leaders evaluating AI in dentistry Much more To learn more about Overjet AI you can visit https://www.overjet.com/ and book a demo or connect with Dr. Barfield on Linkedin - https://www.linkedin.com/in/gordon-barfield-dds-ms-676a9516/ To learn more about mydentist you can visit https://www.mydentist.co.uk/ or connect with Dr. Whitley on Linkedin - https://www.linkedin.com/in/nyree-whitley-2a85b85a/  Subscribe to our channel for more episodes and stay updated on the latest DSO news, insights, and events! If you like our podcast, please give us a ⭐⭐⭐⭐⭐ review on iTunes https://apple.co/2Nejsfa and a Thumbs Up on YouTube.  

Dans cet épisode de Cheminements, nous plongeons au cœur de l'urgence absolue : la méningite. Cette infection foudroyante, qui peut toucher n'importe qui sans prévenir, impose une course contre la montre où le diagnostic précoce est la seule clé pour éviter le décès ou des séquelles irréversibles. À travers le récit bouleversant d'une mère devenue présidente d'association et l'expertise d'un infectiologue, nous explorons comment la collaboration entre patients et soignants sauve des vies et comment les nouvelles technologies diagnostiques transforment la prise en charge à l'hôpital.Les intervenants :Patricia Merhant-Sorel : Présidente de l'association Petit Ange (Ensemble contre la méningite). Après avoir perdu sa fille Gwendoline en 2003, elle consacre son action à l'accompagnement des familles et à la sensibilisation du public et des professionnels de santé.Docteur Nicolas Ettahar : Infectiologue au Centre Hospitalier de Valenciennes. Expert de la réalité clinique des maladies infectieuses, il apporte son regard sur les enjeux de diagnostic et de prévention.Les sujets abordés dans l'épisode :Le témoignage de Patricia sur la perte brutale de sa fille et la création de l'association Petit Ange.Les formes fulgurantes de la maladie : pourquoi l'évolution peut être fatale en moins de 12 heures.L'importance capitale du diagnostic différentiel face à des symptômes parfois trompeurs (fièvre, maux de tête).L'apport des tests rapides (PCR) pour cibler immédiatement le bon traitement antibiotique.Le rôle de la vaccination et des mesures barrières dans la prévention collective.La nécessité d'un dialogue permanent entre les familles, les cliniciens et les industriels du diagnostic.Écriture : Marguerite de RodellecProduction : MedShake StudioCet épisode est enregistré dans le cadre de la première édition de la Journée Patients & Pharma, un événement pour créer un véritable espace de dialogue entre représentants de patients et industrie qui aura lieu le 4 décembre 2025, à la Maison A. Trocadéro. Chers auditeurs, je vous informe que cette journée s'écoutera aussi ! Des épisodes exclusifs du podcast Cheminements seront enregistrés en direct, pour donner la parole à des binômes patients / laboratoires qui viendront raconter leurs collaborations, leurs défis, et parfois même… leurs histoires d'amour professionnelles. Alors si ce sujet vous parle, rejoignez-nous.Ressources :https://patientspharma.com/En ouvrant le dictionnaire, on apprend que "cheminement" désigne une progression graduelle, un mouvement, une avance graduelle.➡ Retrouvez tous les épisodes sur https://www.cheminements.co/❤️ Soutenez-nous gratuitement :Abonnez-vous !Laissez 5 étoiles et un avis sur Apple Podcasts ou Spotify ⭐Cheminements, le podcast santé des femmes, dans vos oreilles chaque semaine.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

What if one of the biggest predictors of falls, balance issues, and even athletic decline wasn't the hips, core, or knees, but the toes? And what if strengthening them could dramatically change outcomes as we age? In this episode, I sit down with Dr. Tom Michaud, a chiropractor, researcher, and internationally recognized expert in foot biomechanics, to explore how weak toes and poor foot function significantly increase fall risk in older adults and limit performance in master athletes. We discuss why foot and ankle health is often overlooked and how it serves as the foundation for balance, speed, and long-term vitality. Dr. Michaud breaks down findings from pivotal studies, including work by researchers like Karen Mickle and Max Piquet, highlighting the role of intrinsic foot muscles such as the flexor hallucis longus and peroneus longus in stability and dynamic movement. We also cover simple at-home tests to assess fall risk and practical exercises that actually improve foot strength. This episode is essential listening for clinicians, athletes, and anyone who wants to stay mobile, resilient, and active as they age.   Key takeaways: Weak toes are a primary predictor of falls in older adults, leading to serious injuries and complications. Enhancing toe strength through targeted exercises can significantly reduce fall risk while boosting athletic performance. Not all traditional foot exercises are effective - exercising the foot muscles in a lengthened position yields better strength gains. Proper assessment of foot architecture and the application of custom strengthening exercises can prevent injuries and improve dynamic performance. Diagnostic tests like the anterior fall envelope and paper grip tests offer valuable insights into an individual's fall risk and foot strength.   More About Dr. Tom Michaud:   In the early nineties, Williams and Wilkins published Dr. Michaud's first textbook, Foot Orthoses and Other Forms of Conservative Foot Care, which was eventually translated into four languages. His next book, Human Locomotion: The Conservative Management of Gait-Related Disorders, which was published in 2012, is used in physical therapy, chiropractic, pedorthic, and podiatry schools around the world. In addition to technical books, Tom also published a book for recreational runners: Injury-Free Running: How to Build Strength, Improve Form, and Treat/Prevent Injuries, now in its second edition. During his 40 years of clinical practice, Dr. Michaud designed and patented numerous diagnostic tools and exercise products to help with the evaluation and treatment of a wide range of sports injuries. Since his recent retirement from clinical practice, Tom is devoting his time to researching, writing, and designing new products in order to develop evidence-based evaluation and treatment protocols that can assist in not just the prevention of sports injuries, but also in ways to stay fit as we age.   Website Instagram Connect with me! Website Instagram Facebook YouTube

"Isolate the Real It: The Diagnostic Approach to Closing More Sales"You didn't lose that sale because of price, product, or timing. You lost it because you never isolated the Real It—the actual thing standing in the way. Most salespeople try to solve everything at once, overwhelming the homeowner and killing the sale before it ever had a chance.In this episode, Sam Wakefield breaks down the diagnostic approach to sales that separates top performers from everyone else. You'll learn how to use qualification questions—not to qualify the homeowner, but to isolate the components of their decision. When you stop guessing and start diagnosing, you close more sales with less resistance.If you've ever walked away from an appointment confused about what went wrong, this episode will show you exactly how to find the Real It and guide your homeowner to clarity. This is the mental shift that changes everything.In This Episode:Why most salespeople lose sales by trying to solve the wrong problemThe combination lock metaphor: how one misaligned piece blocks the entire saleHow to use qualification questions to separate product, payment, timeline, and scopeReal-world language examples of isolating the Real It in appointmentsWhy confidence looks like clarity, not information overloadThe difference between diagnosing and convincingHow to get commitment before you negotiateWhy you can't negotiate with confusion—only clarityResources & Mentions:Win-Win Selling by Doug C. Brown (origin of "the Real It" language)Close It Now Coaching: closeitnow.net/coachingClose It Now Facebook Group: facebook.com/groups/closeitnowEmail Sam: sam@closeitnow.netNew Group Coaching Program:Sam is opening his first group coaching program starting March 2026. Pods of 5 salespeople focused on multiplying close rates and average tickets with integrity. Half the cost of one-on-one coaching. Limited to 5 spots per group. Visit closeitnow.net or email sam@closeitnow.net to learn more.Final Thought:A problem that is well-defined is half-solved. The next time a homeowner hesitates, don't panic. Don't pile on more information. Don't assume what's wrong. Just isolate the Real It. Ask the question that separates the pieces. Find the number that's off on the combination lock. And help them see it clearly. That's when the sale happens.Next Week:How to Right-Size a Project Without Discounting Your Price—the skill that protects your margin while keeping the sale alive.Leave a review on Apple Podcasts or Google to help more salespeople find this show.Google Review Link: https://g.page/r/CbfnnDqTCwQdEAE/review

Eliot Deval revient pendant deux heures, sans concession, sur tous les sujets qui font l'actualité. Vous voulez réagir ? Appelez le 01.80.20.39.21 (numéro non surtaxé) ou rendez-vous sur les réseaux sociaux d'Europe 1 pour livrer votre opinion et débattre sur les grandes thématiques développées dans l'émission du jour.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Tired of watching deals drag on for months while your pipeline stalls and your confidence tanks?Here's the truth most consultants miss: you're the one slowing down your own sales cycle.In this episode, Melisa reveals the four strategies that help consultants close deals faster without discounting, settling, or feeling "salesy."You'll discover why corporate buyers aren't actually the problem (even though it feels that way), and how the delays, stalls, and endless "I'll get back to you” responses are often triggered by how you're showing up in the sales process.This episode dismantles the myth that corporate buyers are always slow and instead puts the focus back on you as the expert, guiding, recommending, and leading your prospects toward clarity and action.Episode Timestamps:[06:01] Why long sales cycles are usually consultant-created and what to do about it[08:23] The Expert Mindset and how certainty speeds up decisions[18:02] The Foot-in-the-Door Offer strategy to generate revenue faster[25:08] How co-creating proposals with your buyer reduces delays and revisions[31:17] The Account Plan and how to stop winging your sales efforts[38:46] 6 questions to self-diagnose where your sales process needs workWhat you'll learn:The hidden consultant behaviors that extend your consulting sales cycle by weeks or even monthsHow to accelerate B2B sales without being pushy or compromising your valuePractical strategies to reduce proposal rework and rescoping delaysHow to lead the buying process with confidence and clarityWhy adopting an expert mindset shortens decision timelinesHow to diagnose and fix weak points in your sales processTopics covered: sales cycle management, consulting business development, B2B sales strategies, client acquisition for consultants, shortening sales timelines, proposal management, consulting sales process, expert positioningStop losing deals to delay. Listen to Episode 256 now and take back control of your sales timeline before another month slips by.Mentioned ResourcesCompanion Resource: Read Chapter 10 in Melisa's book, Grow Your Consulting Business: The 14-Step Roadmap to Make Your Independent Consulting Goals a Reality, https://www.amazon.com/dp/B0CSXJBGVB    Full Show Notes: https://shownotes.melisaliberman.com/episode-256Melisa's Books, Planners & Journals: https://linktr.ee/melisalibermanMentioned in this Episode: Episode 159 - Shorten the Consulting Sales Cycle by Offering a Diagnostic, https://shownotes.melisaliberman.com/episode-159/#more-2340 Want help achieving your consulting business goals? Melisa can help. Click here for more on coaching tailored to you as an independent consulting business owner.

Wayne Broman of Boeck Farm Outfitters has been helping growers with Precision Planting equipment since Cleansweep hit the market. In this episode, he tells Hans and Tyler the story about one of the most difficult troubleshooting scenarios he has come across.

Functional Neurological Disorder (FND) is often misunderstood... but it's real, common, AND treatable. In this episode of Talk Dizzy To Me, vestibular physical therapists Dr. Abbie Ross, PT, NCS and Dr. Carly Lochala, PT, NCS sit down with Dr. Julie Hershberg, PT, NCS to explain what FND is, why it's been minimized in healthcare, and how it overlaps with dizziness, migraine, dysautonomia/POTS, hypermobility/EDS, and vestibular disorders.They break down brain networks like the default mode network and salience network, discuss common clinical clues (variability, attention-related shifts), and explain how treatment often starts with nervous system regulation, trust-building, and whole-person care—not just exercises.If you've been told your symptoms are “all in your head,” this episode is for you.Guest: Dr. Julie Hershberg / Reactive PT Instagram: @reactiveptResources: FND resources hub, reactivept.com/FNDresourcesHosted by:

How can healthcare professionals transform burnout and trauma into a revitalized life and practice?In this special episode of Heartline: Changemaking in Healthcare, Dr. Andrea Austin reads from her book Revitalized, focusing on the chapter "The Revitalization." She reflects on her own soul-level burnout at the end of the pandemic, sharing a formula for change: inflection point + inner work + clarity = revitalization. Drawing from personal experiences and expert insights, she emphasizes embracing the past's pain as part of growth, avoiding trauma loops, and intentionally "doing the work" for self-improvement.You'll hear how to:Recognize burnout as a chronic issue requiring inner reflection, not just quick fixes, and frame it as an opportunity for revitalization beyond "bouncing back."Differentiate top-down therapies (like CBT and talk therapy) from bottom-up approaches (like EMDR, somatic experiencing, and art therapy) for trauma healing, especially in high-stress fields like medicine.Understand coaching as a future-focused partnership for unlocking potential, while knowing when to seek therapy first, given high rates of PTSD (40%) and depression (30%) among healthcare workers.Navigate "VUCA" (volatility, uncertainty, complexity, ambiguity) in healthcare, including life quakes like job loss or health crises, and avoid maladaptive coping like overconsumption or addictions.Build vulnerability in hard conversations, reflect on perfectionism, and beware predatory coaching programs while prioritizing ethical, supportive resources.If you're a healthcare professional grappling with burnout, trauma, or the desire for more fulfillment, this episode offers empathetic guidance, reflective questions, and actionable steps to craft your own revitalization.

In this episode, Dr. Erica Lacher and show host Justin Long talk about the wide variety of diagnostic tools that veterinarians use, what information they provide, and how veterinarians decide the best diagnostic options on a limited budget. Topics include imaging, blood tests, and more!

When your child survives one medical emergency only to face another, parenting becomes a constant act of advocacy and courage. Today's guest joins us to share her daughter's journey with rare and complex medical conditions, from early respiratory failure and unexplained hospitalizations to epilepsy, lung disease, and life with medical uncertainty. As a military spouse navigating deployments, Brittany shares what it means to walk this path largely alone, trust her instincts as a mother, and fight to be believed by medical professionals. This episode explores navigating rare disease without clear answers, the life-changing impact of compassionate child life support, supporting siblings through medical trauma, and how rituals, play, and community help families find hope and meaning in the midst of chaos. Download our free Children's Hospital Passport to help empower your child and family during hospital stays. Sponsored in part by HealthWell Foundation—learn how you can help families afford life-saving medications at healthwellfoundation.org.   Resources from today's episode: Medical Support:  Stanford Children's Health  Undiagnosed Diseases Network Nonprofit & Community Support: Live Like JoJo Foundation The Meg Foundation (Pediatric Pain & Poke Plans)  Brave Bears Club (Epilepsy Support) Child Life Mommy CHYP  Connect with Brittany Follow Brittany's journey as she shares life as a medical mom, military spouse, and advocate.    Connect & Support from Child Life On Call  Subscribe: Never miss an episode on Apple Podcasts or Spotify. Visit insidethechildrenshospital.com to easily search stories and episodes Follow us on Instagram for updates and opportunities to connect with other parents Download SupportSpot: receive Child Life tools at your fingertips. Leave a Review: It helps other families find us and access our resources!   Keywords: Rare disease parenting, Medical motherhood, Medically complex child, Pediatric lung disease, Pediatric epilepsy, Intractable epilepsy, PICU parent experience, Military family healthcare, Parent advocacy in healthcare, Child life specialist support, Sibling support during hospitalization, Parenting after medical trauma, Coping with chronic illness, Undiagnosed disease journey, Hospital parent support Medical information provided is not a substitute for professional advice—please consult your care team  

In this conversation, I explore a fascinating paradox in our relationship with artificial intelligence.Why do we demand absolute perfection from AI while accepting human error as inevitable? When an LLM hallucinates or cites fake sources, I get frustrated. But when a colleague misspeaks or misremembers, I give them grace. Why the double standard?I walk through the reality of human error across industries:* Diagnostic mistakes happen in 5-20% of doctor visits* 80% of aviation accidents trace back to human error* 20% of Big Four audits have significant deficiencies* Even elite professionals only achieve 90-95% accuracy.The thread tying all of this together is simple but uncomfortable: our imperfections are what make us human and interesting. AI-generated content feels soulless. You can sense it. It lacks emotion, depth, playfulness, and personality.I believe we're heading toward an age where we'll pay a premium for human-generated content, art, and music. We think we can scale the human experience with AI, but what we'll find instead is an overly perfect, emotionless dark age of art and culture.The choice isn't between perfect AI or imperfect humans. It's about deciding which imperfections we're willing to live with.TIMESTAMPS00:00 Hello from Australia!01:16 We Expect Perfection out of AI and Not in Humans, Why?06:41 The Paradox of Perfection in AI and Humanity07:05 Mentoring Opportunities07:26 The Book of the Week08:34 Grab My Guidebooks08:51 Check this outLinkshttps://www.who.int/news-room/fact-sheets/detail/patient-safetyhttps://www.sciencedirect.com/science/article/pii/S2666691X23000246https://tax.thomsonreuters.com/news/audit-deficiency-rate-drops-in-2024-in-sign-of-improvement/https://www.researchgate.net/publication/1907590_Thinking_is_Bad_Implications_of_Human_Error_Research_for_Spreadsheet_Research_and_PracticeCONNECT WITH MENewsletter: https://www.ninasnotes.xyzLongevity.Technology Unlocked Podcast: https://longevity.technology/unlocked/Longevity Guidebooks: https://ninapatrick.xyz/guidebooksMentoring: https://ninapatrick.xyz/startup-mentor/LinkedIn: https://www.linkedin.com/in/ninapatrick/Website: https://www.ninapatrick.xyz Get full access to Nina's Notes at www.ninasnotes.xyz/subscribe

In this special episode, recorded live at the 2025 Genomics England Research Summit, host Adam Clatworthy is joined by parents, clinicians and researchers to explore the long, uncertain and often emotional journey to a genetic diagnosis. Together, they go behind the science to share what it means to live with uncertainty, how results like variants of uncertain significance (VUS) are experienced by families, and why communication and support matter just as much as genomic testing and research. The panel discuss the challenges families face when a diagnosis remains out of reach, the role of research in refining and revisiting results over time, and how collaboration between researchers, clinicians and participants could help shorten diagnostic journeys in the future. Joining Adam Clatworthy, Vice-Chair for the Participant Panel, on this episode are: Emma Baple – Clinical geneticist and Medical Director, South West Genomic Laboratory Hub  Jamie Ellingford – Lead genomic data scientist, Genomics England  Jo Wright – Member of the Participant Panel and Parent Representative for SWAN UK  Lisa Beaton - Member of the Participant Panel and Parent Representative for SWAN UK  Linked below are the episodes mentioned in the episode:  What is the diagnostic odyssey?  What is a Variant of Uncertain Significance?  Visit the Genomics England Research Summit website, to get your ticket to this years event. You can download the transcript, or read it below. Sharon: Hello, and welcome to Behind the Genes. My name is Sharon Jones and today we're bringing you a special episode recorded live from our Research Summit held in June this year. The episode features a panel conversation hosted by Adam Clatworthy, Vice-Chair of the Participant Panel. Our guests explore navigating the diagnostic odyssey, the often-complex journey to reaching a genetic diagnosis. If you'd like to know more about what the diagnostic odyssey is, check our bitesize explainer episode, ‘What is the Diagnostic Odyssey?' linked in the episode description. In today's episode you may hear our guests refer to ‘VUS' which stands for a variant of uncertain significance. This is when a genetic variant is identified, but its precise impact is not yet known. You can learn more about these in another one of our explainer episodes, “What is a Variant of Uncertain Significance?” And now over to Adam. -- Adam: Welcome, everyone, thanks for joining this session. I'm always really humbled by the lived experiences and the journeys behind the stories that we talk about at these conferences, so I'm really delighted to be hosting this panel session. It's taking us behind the science, it's really focusing on the people behind the data and the lived experiences of all the individuals and the families who are really navigating this system, trying to find answers and really aiming to get a diagnosis – that has to be the end goal. We know it's not the silver bullet, but it has to be the goal so that everyone can get that diagnosis and get that clarity and what this means for their medical care moving forwards.    So, today we're really going to aim to demystify what this diagnostic odyssey is, challenging the way researchers and clinicians often discuss long diagnostic journeys, and we'll really talk about the vital importance of research in improving diagnoses, discussing the challenges that limit the impact of emerging research for families on this odyssey and the opportunities for progress. So, we've got an amazing panel here. Rather than me trying to introduce you, I think it's great if you could just introduce yourselves, and Lisa, I'll start with you. Lisa: Hi, I'm Lisa Beaton and I am the parent of a child with an unknown, thought to be neuromuscular, disease. I joined the patient Participant Panel 2 years ago now and I'm also a Parent Representative for SWAN UK, which stands of Syndromes Without A Name. I have 4 children who have all come with unique and wonderful bits and pieces, but it's our daughter who's the most complicated. Adam:  Thank you. Over to you, Jo. Jo:  Hi, I'm Jo Wright, I am the parent of a child with an undiagnosed genetic condition.  So I've got an 11-year-old daughter. 100,000 Genomes gave us a VUS, which we're still trying to find the research for and sort of what I'll talk about in a bit.  And I've also got a younger daughter. I joined the Participant Panel just back in December. I'm also a Parent Rep for SWAN UK, so Lisa and I have known each other for quite a while through that. Adam:  Thank you, Jo.  And, Jamie, you're going to be covering both the research and the clinician side and you kind of wear 2 hats, so, yeah, over to you. Jamie:  Hi, everyone, so I'm Jamie Ellingford and, as Adam alluded to, I'm fortunate and I get to wear 2 hats. So, one of those hats is that I'm Lead Genomic Data Scientist for Rare Disease at Genomics England and so work as part of a really talented team of scientists and engineers to help develop our bioinformatic pipelines, so computational processes. I work as part of a team of scientists and software engineers to develop the computation pipelines that we apply at Genomics England as part of the National Health Service, so the Genomic Medicine Service that families get referred to and recruited to, and we try to develop and improve those. So that's one of my hats. And the second of those is I am a researcher, I'm an academic at the University of Manchester, and there I work really closely with some of the clinical teams in the North West to try and understand a little bit more about the functional impact of genomic variants on kind of how things happen in a cell. So, we can explore a little bit more about that but essentially, it's to provide a little bit more colour as to the impact that that genomic variant is having. Adam: Great, thank you, Jamie. Over to you, Emma. Emma: My name's Emma Baple, I'm an academic clinical geneticist in Exeter but I'm also the Medical Director of the South West genomic laboratory hub, so that's the Exeter and Bristol Genomics Laboratory. And I wear several other hats, including helping NHS England as the National Specialty Advisor for Genomics. Adam: Thank you all for being here. I think it's really important before we get into the questions just to ground ourselves in like those lived experiences that yourself and Jo and going through. So, Lisa, I'm going to start with you. The term ‘diagnostic odyssey' gets bandied around a lot, we hear about it so many times, but how does that reflect your experience that you've been through and what would you like researchers and clinicians to understand about this journey that you're on, essentially? Lisa: So I think ours is less an odyssey and more of a roller-coaster, and I say that because we sort of first started on a genetic journey, as it were, when my daughter was 9 weeks of age and she's now 16½ – the half's very important – and we still have no answers. And we've sort of come a bit backwards to this because when she was 6 months old Great Ormond Street Hospital felt very strongly that they knew exactly what was wrong with her and it was just a case of kind of confirmation by genetics. And then they sent off for a lot of different myasthenia panel genes, all of which came back negative, and so having been told, “Yes, it's definitely a myasthenia, we just need to know which one it is,” at 4 years of age that was removed and it was all of a sudden like, “Yeah, thanks, sorry.” And that was really hard actually because we felt we'd had somewhere to hang our hat and a cohort of people with very similar issues with their children, and then all of a sudden we were told, “No, no, that's not where you belong” and that was a really isolating experience. I can remember sort of saying to the neuromuscular team, “Well is it still neuromuscular in that case?” and there was a lot of shrugging of shoulders, and it just…  We felt like not only had we only just got on board the life raft, then we'd been chucked out, and we didn't even have a floaty. And in many ways I think I have made peace with the fact that we don't have a genetic diagnosis for our daughter but it doesn't get easier in that she has her own questions and my older children – one getting married in August who's already sort of said to me, you know, “Does this have implications for when we have children?”  And those are all questions I can't answer so that's really hard. Adam:  Thank you, Lisa. Yourself, Jo, how would you describe the odyssey that you're currently experiencing? Jo: So my daughter was about one when I started really noticing that she was having regressions. They were kind of there beforehand but, I really noticed them when she was one, and that's when I went to the GP and then got referred to the paediatrician. So initially we had genetic tests for things like Rett syndrome and Angelman syndrome, which they were all negative, and then we got referred on to the tertiary hospital and then went into 100,000 Genomes. So we enrolled in 100,000 Genomes at the beginning of 2017, and we got our results in April of 2020, so obviously that was quite a fraught time. Getting our results was probably not as you would want to do it because it was kind of over the phone and then a random letter. So, what I was told in that letter was that a variant of uncertain significance had been identified and they wanted to do further research to see if it might be more significant. So we were to be enrolled into another research project called Splicing and Disease, which wasn't active at the time because everything had been put on hold for COVID, but eventually we went into that. So, I didn't know what the gene was at that point, when I eventually got the form for going to get her bloods done…  So that went off and then that came back and the geneticist said, “That gives us some indication that it is significant.” So, since that point it's been trying to find more information and research to be able to make it a diagnosis. There have been 2 sort of key things that have happened towards that but we're still not there. So one of the things is that a research paper came out earlier this year so that's kind of a little bit more evidence, it's not going to give us a diagnosis but it kind of, you know, sits there. And the other thing is that my geneticist said, “Actually, yeah, it looks like it's an important change.”  That's as far as we've got. So we've still got work to do to make it a diagnosis or not.  Obviously if it is a diagnosis, it is still a one-of-a-kind diagnosis, so it doesn't give me a group to join or that kind of thing. But now I've got that research paper that I've read and read, and asked ChatGPT to verify that I've understood it right in some places, you know, with the faith that we put into ChatGPT (laughs), I've got a better understanding and I've got something now that I can look back on, the things that happened when my daughter was one, 2, 3, 4 and her development was all over the place and people thought that I was slightly crazy for the things I was saying, that “Actually, no, I can see what's happening.” So, it's like the picture's starting to come into focus but there's work to do. I haven't got a timeframe on that, I don't know when it's going to come together. And I always say that I'm a prolific stalker of the postman; ever since our first genetic tests you're just constantly waiting for the letters to drop through the door. So a diagnostic odyssey to me is just waiting for random events. Adam: I think what you've both kind of really clearly elaborated on is how you're the ones that are having to navigate this journey, you're the ones that are trying to piece this puzzle together, and the amount of time you're investing, all whilst navigating and looking after your child and trying to cope with the daily lived experience as well. And something you've both touched on that I'd love to draw out more is about how exactly was the information shared with you about the lack of diagnosis or the VUS or what's going on, because in our case you get this bit of paper through the post that has all these numbers and it's written in clinical speak and we had no conversation with the geneticist or the doctors. You see this bit of paper and you're reading it, scared for what the future will hold for your child, but I'd love to know like how were you communicated whilst all this is going on, how did you actually find out the next steps or any kind of future guidance. Lisa: So I think in our case we kept sort of going onto neuromuscular appointments, and I think for probably the first 5 years of my daughter's life I kind of had this very naïve thought that every time we turned up to an appointment it would be ‘the one' and then…   I think it would've been really helpful actually in those initial stages if they had said to us, “Actually, we don't know when this is going to happen, if it's even going to happen, you need to kind of prepare yourself for that.” It sounds fairly obvious to say but you don't know what you don't know. And in some ways we were getting genetic test results back for some really quite horrible things and they would tell us, “Oh it's good news, this mitochondrial disorder hasn't come up,” and so part of you is like, “Yay!” but then another part of you is thinking, “Well if it's not that what is it?” And we've very much kind of danced around and still don't really have an answer to whether it's life-limiting. We know it's potentially life-threatening and we have certain protocols, but even that is tricky. We live in North Yorkshire, and our local hospital are amazing. Every time we go in, if it's anything gastro-related, they say to me, “What's the protocol from Great Ormond Street?” and I say, “We don't have one” (laughs) and that always causes some fun. We try to stay out of hospitals as much as we absolutely can and do what we can at home but, equally, there's a point where, you know, we have to be guided by where we're going with her, with the path, and lots of phone calls backwards and forwards, and then is it going to be a transfer down to Great Ormond Street to manage it. And actually the way I found out that nothing had been found from 100,000 Genomes was in a passing conversation when we had been transferred down to Great Ormond Street and we'd been an inpatient for about 6 weeks and the geneticist said to me, “So obviously with you not having a diagnosis from the 100,000 Genomes…” and I said, “Sorry?  Sorry, what was that?  You've had the information back?”  And she said, “Well, yes, did nobody write to you?” and I said, “No, and clearly by my shock and surprise.” And she was a bit taken aback by that, but it happened yet again 2 years later (laughs) when she said, “Well you know everything's been reanalysed” and I said, “No.”  (Laughs)  And, so that's very much, it still feels an awful lot like I'm doing the heavy lifting because we're under lots of different teams and even when they're working at the same hospital they don't talk to each other. And I do understand that they're specialists within their own right, but nobody is really looking at my daughter holistically, and there are things that kind of interrelate across.    And at one of the talks I attended this morning they were talking about the importance of quality of life, and I think that is something that has to be so much more focused on because it's hard enough living without a diagnosis, but when you're living with a bunch of symptoms that, I think the best way I can describe it is at the moment we've got the spokes of the umbrella but we don't have the wrapper, and we don't know where we're going with it. We can't answer her questions, we can't even necessarily know that we're using the most effective treatments and therapies for her, and she's frustrated by that now, being 16, in her own right, as well as we are. And I'm panicking about the navigation towards Adult Services as well because at the minute at least we have a clinical lead in our amazing local paediatrician but of course once we hit and move into that we won't even have him and that's a really scary place to be, I think. Adam: Jo, is there anything you wanted to add on that in terms of how you've been communicated to whilst all this is going on? Jo: Yeah, so I think part of what makes it difficult is if you're across different hospitals because they're not necessarily going to see the same information. So obviously it was a bit of a different time when I got our results, but I got our results on a virtual appointment with a neurologist in one hospital, in the tertiary hospital, and because he could see the screen because it was the same hospital as genetics, and he said, “Oh you've got this” and then the letter came through later. When I had my next appointment with the neurologist in our primary hospital, or secondary care, whatever it's called, in that hospital, he hadn't seen that, so I'm telling him the results, which isn't ideal, but it happens quite a lot. What I think is quite significant to me is the reaction to that VUS.  I have to give it, the doctors that look after my daughter are brilliant, and I'm not criticising them in any way but their reaction to a VUS is “I'm so grateful for the persistence to get to a diagnosis.” Neurologists are a bit more like “Oh it's a VUS so it might be significant, it might be nothing.” Actually, as a patient, as in a parent, you actually want to know is it significant or not, “Do I look at it or not?” And, I mean, like I said, there were no research papers to look at before anyway until a few months ago so I didn't have anything to look at, but I didn't want to look at it either because you don't want to send yourself off down a path. But I think that collective sort of idea that once someone gets a VUS we need a pathway for it, “What do we do with it, what expectation do we set the patients up with and what is the pathway for actually researching further?” because this is where we really need the research. Adam:  Thank you, Jo. So, Emma, over to you in terms of how best do you think clinicians can actually support patients at navigating this odyssey and what's the difference between an initial diagnosis and a final diagnosis and how do you then communicate that effectively to the patients and their family?   Emma: So I think a key thing for me, and it's come up just now again, is that you need to remember as a doctor that the things you say at critical times in a patient's or parent's journeys they will remember – they'll remember it word for word even though you won't – and thinking about how to do that in the most sensitive, empathetic, calm, not rushed way is absolutely key.   And there are some difficulties with that when you're in a very high-pressure environment but it is absolutely crucial, that when you are communicating information about test results, when you're talking about doing the test in the first place, you're consenting the family, you're explaining what you're trying to do and those conditions, you balance how much information you give people.    So, you were talking earlier about “So you haven't got this diagnosis, you haven't got that diagnosis,” I often think it's…  We're often testing for numerous different conditions at the same time, I couldn't even list them all to the parents of the children or the patient that I'm testing. It's key to try and provide enough information without overwhelming people with so much information and information on specific conditions you are just thinking about as a potential.  Sometimes very low down your list actually but you can test for them.    Because people go home and they use the internet and they look things up and they get very, very worried about things. So, for me it's trying to provide bite-sized amounts of information, give it the time it deserves, and support people through that journey, tell them honestly what you think the chance of finding a diagnosis is. If you think it's unlikely or you think you know, sharing that information with family is helpful.   Around uncertainty, I find that a particular challenge. So, I think we've moved from a time when we used to, in this country, declare every variant we identified with an uncertain significance. Now, if we remember that we've all got 5 million variants in our genome, we've all got hundreds and hundreds… thousands and thousands, in fact, of variants of uncertain significance in our genetic code. And actually, unless you think a variant of uncertain significance genuinely does have a probability of being the cause of a child's or a patient's condition, sharing that information can be quite harmful to people.    We did a really interesting survey once when we were writing the guidelines for reporting variants of uncertain significance a few years ago. We asked the laboratories about their view of variants of uncertain significance and we asked the clinicians, and the scientists said, “We report variants of uncertain significance because the clinicians want them” and the clinicians said, “If the labs put the variant of uncertain significance on the report it must be important.” And of course, if you're a parent, if the doctor's told you the variant is a variant of uncertain significance of course you think it's important.    So, we should only be sharing that information, in my opinion, if it genuinely does have a high likelihood of being important and there are things that we can do. And taking people through that journey with you, with the degree of likelihood, the additional tests you need to do and explaining to them whether or not you think you will ever clarify that, is really, really key because it's very often that they become the diagnosis for the family.  Did I cover everything you think's important, both of you?  Lisa: I think the one thing I would say is that when you are patient- or parent-facing, the first time that you deliver that news to the parent… you may have delivered that piece of news multiple times and none of us sit there expecting you to kind of be overcome with emotion or anything like that but, in the same way that perhaps you would've had some nerves when, particularly if it was a diagnosis of something that was unpleasant, you know, to hold onto that kind of humanity and humility. Because for those patients and parents hearing that news, that is the only time they're ever hearing that, and the impact of that, and also, they're going on about with their day, you don't know what else they're doing, what they're juggling.    We're not asking you all to be responsible for kind of, you know, parcelling us up and whatnot but the way information is imparted to us is literally that thing we are all hanging our hats on, and when we're in this kind of uncertainty, from my personal experience I'm uncomfortable, I like to be able to plan, I'm a planner, I'm a researcher, I like to sort of look it up to the nth degree and that, and sitting in a place without any of that is, it's quite a difficult place to be. And it's not necessarily good news for those parents when a test comes back negative, because if it's not that then what is it, and that also leaves you feeling floundering and very isolated at times.  Adam: Yeah, and you touched upon the danger of like giving too much information or pushing families down a particular route, and then you have to pull them out of it when it's not that.   You talked about the experience you had, you felt like you'd found your home and then it's like, “Well, no, no, sorry, actually we don't think it's that.” And you've invested all of your time and your emotion into being part of that group and then you're kind of taken away again. So it's to the point where you have to be really sure before you then communicate to the families, and obviously in the meantime the families are like, “We just need to know something, we need to know,” and it's that real fine line, isn't it?    But, Jamie, over to you. Just thinking about the evolving nature of genomic diagnosis, what role does research play in refining or confirming a diagnosis over time?  Jamie: So it's really, really difficult actually to be able to kind of pinpoint one or 2 things that we could do as a community of researchers to help that journey, but perhaps I could reflect on a couple of things that I've seen happen over time which we think will improve things. And one of that's going back to the discussion that we've just had about how we classify genetic variants. And so, behind that kind of variant of uncertain significance there is a huge amount of effort and emotion from a scientist's side as well because I think many of the scientists, if not all, realise what impact that's going to have on the families.   And what we've tried to do as a community is to make sure that we are reproducible, and if you were to have your data analysed in the North West of England versus the South West that actually you'd come out with the same answer. And in order to do that we need guidance, we need recommendations, we need things that assist the scientists to actually classify those variants.  And so, what we have at the moment is a 5 point scale which ranges from benign to likely benign, variant of uncertain significance, unlikely pathogenic variant and pathogenic variant. It's objective as to how we classify a variant into one of those groups and so it's not just a gut feeling from a scientist, it's kind of recordable measurable evidence that they can provide to assist that classification.   So in many instances what that does is provide some uncertainty, as we've just heard, because it falls into that zone of variant of uncertain significance but what that also does is provide a framework in which we can generate more evidence to be able to classify it in one direction or another to become likely pathogenic or to become likely benign. And as a research community we're equipped with that understanding –– and not always with the tools but that's a developing area – to be able to do more about it.   What that doesn't mean is that if we generate that evidence that it can translate back into the clinic, and actually that's perhaps an area that we should discuss more. But kind of just generating that evidence isn't always enough and being able to have those routes to be able to translate back that into the hands of the clinicians, the clinical scientists, etc, is another challenge. Adam:  And how do you think we can drive progress in research to deliver these answers faster, to really try and shorten those diagnostic journeys, like what are the recommendations that you would say there? Jamie:  So being able to use the Genomics England data that's in the National Genomic Reference Library, as well as kind of other resources, has really transformed what we can do as researchers because it enables teams across the UK, across the world to work with data that otherwise they wouldn't be able to work with.   Behind that there's an infrastructure where if researchers find something which they think is of interest that can be reported back, it can be curated and analysed by teams at Genomics England and, where appropriate, kind of transferred to the clinical teams that have referred that family. And so having that pathway is great but there's still more that we can do about this. You know, it's reliant on things going through a very kind of fixed system and making sure that clinicians don't lose contact with families – you know, people move, they move locations, etc. And so, I think a lot of it is logistical and making sure that the right information can get to the right people, but it all falls under this kind of umbrella of being able to translate those research findings, where appropriate, into clinical reporting.   Adam:  Thank you. And, Emma, is there anything you would add in terms of like any key challenges that you think need to be overcome just to try and shorten the journeys as much as possible and find the answers to get a diagnosis?  Emma: I think trying to bridge that gap between some of the new technologies and new approaches that we've got that we can access in a research context and bringing those into diagnostics is a key area to try to reduce that diagnostic odyssey, so I really want to see the NHS continuing to support those sorts of initiatives.   We're very lucky, as Jamie said, the National Genomic Research Library has been fundamental for being able to reduce the diagnostic odyssey for large numbers of patients, not just in this country but around the world, and so trying to kind of look at how we might add additional data into the NGRL, use other research opportunities that we have in a more synergistic way with diagnostics I think is probably key to being able to do that.    We are very lucky in this country with the infrastructure that we've got and the fact that everything is so joined up. We're able to provide different opportunities in genomics for patients with rare conditions that aren't so available elsewhere in the world.  Adam: Great, thank you. I think we're it for time, so thank you very much to the panel. And I'd just say that if you do have any further questions for ourselves as participants then we're only too happy to pick those up. Thank you for lasting with us ‘til the end of the day and hope to see you soon.  -- Sharon: A huge thank you to our panel, Adam Clatworthy, Emma Baple, Jo Wright, Lisa Beaton and Jamie Ellingford, for sharing their insights and experiences. Each year at the summit, the Behind the Genes stage hosts podcast style conversations, bringing together researchers, clinicians and participants to discuss key topics in genomics.  If you're interested in attending a future Genomics England Research Summit, keep an eye out on our socials. If you'd like to hear more conversations like this, please like and subscribe to Behind the Genes on your favourite podcast app. Thank you for listening.    I've been your host, Sharon Jones. The podcast was edited by Bill Griffin at Ventoux Digital and produced by Deanna Barac.

In this episode of "PICU Doc On Call," Drs. Pradip Kamat and Rahul Damania discuss the acute management of a 14-year-old boy with severe rectal bleeding and hypertension, ultimately diagnosed with inflammatory bowel disease (IBD). They review the approach to pediatric lower GI bleeding, diagnostic workup, and imaging, emphasizing early recognition and resuscitation. They outline IBD management, including steroids, biologics such as infliximab, and nutritional support, while highlighting the importance of screening for infections before immunosuppression. The episode provides practical insights for PICU physicians on handling acute GI emergencies in children.Show Nighlights: Clinical case of a 14-year-old male with hypertension and rectal bleeding.Diagnosis of inflammatory bowel disease (IBD) following significant blood loss.Approach to pediatric rectal bleeding and its implications.Diagnostic workup including laboratory tests and imaging modalities.Management strategies for IBD in acute pediatric care.Importance of early recognition and resuscitation in cases of shock.Physiological principles related to blood loss and shock in children.Differential diagnoses for lower gastrointestinal bleeding in pediatrics.Initial evaluation and stabilization protocols for pediatric patients.Nutritional support and multidisciplinary care in managing IBD. References:Romano C, Oliva S, Martellossi S, et al. Pediatric gastrointestinal bleeding: Perspectives from the Italian Society of Pediatric Gastroenterology. World J Gastroenterol. 2017;23(8):1326-1337.Pai AK, Fox VL. Gastrointestinal bleeding and management. Pediatr Clin North Am. 2017;64(3):543-561.Padilla BE, Moses W. Lower gastrointestinal bleeding and intussusception. Surg Clin North Am. 2017;97(1):63-80.Kaur M, Dalal RL, Shaffer S, Schwartz DA, Rubin DT. Inpatient management of inflammatory bowel disease-related complications. Clin Gastroenterol Hepatol. 2020;18(11):2417-2428.Ashton JJ, Ennis S, Beattie RM. Early-onset paediatric inflammatory bowel disease. Lancet Child Adolesc Health. 2017;1(2):147-158.Bouhuys M, Lexmond WS, van Rheenen PF. Pediatric inflammatory bowel disease. Pediatrics. 2022;150(6):e2022059341.Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 2015;169(11):1053-1060.Conrad MA, Rosh JR. Pediatric Inflammatory Bowel Disease. Pediatr Clin North Am. 2017 Jun;64(3):577-591.

Stephen Ross forgot who he hired at his introductory press conference and Pat Leonard sits in and discusses the changes taking place since John Harbaugh has taken over the New York Giants.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Benjamin Tolchin, MD, MS, FAAN, joins the podcast to provide clinical perspective on the recently published American Academy of Neurology (AAN) guidelines on functional seizures, drawing on his role as a contributing author to the recommendations. Tolchin, Director of the Center for Clinical Ethics at Yale New Haven Health and Associate Professor of Neurology at Yale School of Medicine, discusses what prompted the development of the first AAN guideline in this space and how the evidence base evolved to support formal recommendations. The conversation explores key considerations around diagnosing functional seizures, including history, semiology, EEG use, and the growing role of video documentation. Tolchin also addresses how clinicians should approach psychiatric comorbidities and co-occurring epilepsy, the evidence supporting psychological interventions, why pharmacologic therapies are not recommended for functional seizures themselves, and where major gaps remain in research to advance care in the years ahead.Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.Episode Breakdown: 1:10 – Why growing evidence prompted the first AAN guideline on functional seizures 3:20 – Diagnostic priorities including history, semiology, EEG, and video documentation 6:15 – Assessing psychiatric comorbidities and co-occurring epilepsy in functional seizures 9:15 – Neurology News Minute 11:30 – Evidence supporting psychotherapy for functional seizures 14:50 – Pharmacological evidence and use of antiseizure medications for functional seizures 18:35 – Barriers to advancing clinical trials in functional seizures 22:05 – Research priorities to refine treatment and long-term outcomes The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Subcutaneous Copper Histidinate as First Treatment for Pediatric Menkes Disease sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis High-Dose Nusinersen Gains European Commission Approval for Spinal Muscular Atrophy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

203. The Human Element in Leadership (with Helen Honisett)   In this episode of the Visibility Factor podcast, host Sue Barber speaks with Helen Honisett, CEO of Defy Expectations, about her unique approach to leadership. They discuss the importance of clarity in leadership, the impact of generational differences, and the concept of 'love leadership' which emphasizes human connection and care. Helen shares insights on the use of diagnostic tools for leadership development and the role of AI in enhancing leadership effectiveness. The conversation highlights the need for strategic thinking in leadership and the importance of understanding one's value in the evolving workplace. Takeaways Helen emphasizes the importance of clarity in leadership. Great leadership impacts personal wellbeing and professional development. Generational differences can enhance workplace dynamics. Love leadership focuses on human connection and care. Diagnostic tools can identify leadership strengths and weaknesses. AI should enhance human leadership, not replace it. Strategic thinking is crucial for effective leadership. Organizations need to invest wisely in leadership development. Cultural ROI is as important as financial ROI in leadership. Understanding one's value is key in the age of AI.   The book that Helen recommends is Letting Go by David R. Hawkins   Helen's website: https://www.defyexpectations.co.uk/ LinkedIn: https://www.linkedin.com/in/hhonisett/   Link to Order Your Journey to Visibility Workbook   Thank you for listening to The Visibility Factor Podcast!    Check out my website to order my book and view the  videos/resources for The Visibility Factor book and Your Journey to Visibility Workbook. As always, I encourage you to reach out! You can email me at hello@susanmbarber.com. You can also find me on social media everywhere –Facebook, LinkedIn, and of course on The Visibility Factor Podcast! I look forward to connecting with you!       If you liked The Visibility Factor Podcast, I would be so grateful if you could subscribe and leave a review wherever you listen to podcasts! It helps the podcast get in front of more people who can learn how to be visible too!       

Experience is your greatest asset—until it creates your biggest blind spot. In the Season 2 premiere of Windshield Time, Chris Elmore and Matthew Barbosa dismantle the myth that "seasoned pros don't need checklists." If you're relying on your gut to diagnose, you're leaving money, trust, and your reputation on the table. We dive into why the diagnostic checklist isn't about finding the problem—it's about the "Juggernaut Strike": making one undeniable point that secures the sale before you even open your mouth. In this episode, you'll learn: The Routine Trap: How your "automatic" expertise creates invisible blind spots. Troubleshooting vs. Diagnosing: Why finding the fix is only 10% of the job. The "Greens" Strategy: How documenting what isn't broken builds more trust than finding what is. Translation Over Technicality: Using the checklist as a shared language with the customer. The Documentation Premium: Why knowledge has zero value until it's shared with the person paying the bill.

Sign up for my free class REJECTION SENSITIVITY 101 here!In this episode, I'm breaking down five research-backed facts about ADHD that should fundamentally change how we think about diagnosis, medication, and long-term care. These aren't hot takes. They're uncomfortable truths.Here's what we're covering:• 80% of people stop ADHD medication within the first year—not because it “didn't work,” but because the system failed them• Diagnostic criteria are still wildly outdated, especially for adults, women, and older adults• Many people seek diagnosis because someone else pushes them to, which makes staying in treatment much harder• The “antibiotic fantasy” of ADHD treatment—why trying meds once and quitting is almost guaranteed to fail• Too many clinicians treating ADHD aren't properly trained, creating shame, confusion, and poor outcomesThis episode is about naming what's broken—so you can advocate for better care, better information, and better support.If you have ADHD, love someone who does, or work with ADHD clients or patients… this is required listening.Watch this episode on YouTubeWant help with your ADHD? Join FOCUSED!Have questions for Kristen? Call 1.833.281.2343Hang out with Kristen on Instagram and TikTokSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.